

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 12/14/2006

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/544,163	08/22/2006	Hector F DeLuca	1256-01083	6427
26753 75	90 12/14/2006		EXAMINER	
ANDRUS, SCEALES, STARKE & SAWALL, LLP			QAZI, SABIHA NAIM	
100 EAST WIS MILWAUKEE,	CONSIN AVENUE, SUIT WI 53202	E 1100	ART UNIT PAPER NUMBER	
,			1616	-

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/544,163 DELUCA E		T AL.			
Office Action Summary	Examiner	Art Unit				
	Sabiha Qazi	1616				
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet	with the correspondence ac	ldress			
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailine earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMU 136(a). In no event, however, may will apply and will expire SIX (6) No. c, cause the application to become	NICATION.  y a reply be timely filed  NONTHS from the mailing date of this ce  ABANDONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 26 A	ugust 2006.					
	s action is non-final.					
	·					
closed in accordance with the practice under E	*	•				
Disposition of Claims			•			
4) Claim(s) <u>1-11,17,18,20,22,24,26 and 28</u> is/are	pending in the applicat	ion.				
4a) Of the above claim(s) is/are withdra		,				
5) Claim(s) is/are allowed.			• *			
6)⊠ Claim(s) <u>1-11,17,18,20,22,24,26 and 28</u> is/are	rejected.					
7) Claim(s) is/are objected to.		•				
8) Claim(s) are subject to restriction and/o	or election requirement.					
Application Papers		. •				
9) The specification is objected to by the Examine	er.					
10) The drawing(s) filed on is/are: a) acc	epted or b) objected	to by the Examiner.				
Applicant may not request that any objection to the	drawing(s) be held in abe	yance. See 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correct	tion is required if the drawi	ng(s) is objected to. See 37 Cl	FR 1.121(d).			
11) ☐ The oath or declaration is objected to by the Ex	xaminer. Note the attach	ned Office Action or form P1	ГО-152.			
Priority under 35 U.S.C. § 119						
12)⊠ Acknowledgment is made of a claim for foreign a)⊠ All b)□ Some * c)□ None of:	priority under 35 U.S.C	s. § 119(a)-(d) or (f).				
1. ☐ Certified copies of the priority document	s have been received	•	•			
2. Certified copies of the priority document		Application No.				
3. Copies of the certified copies of the prio			Stage			
application from the International Bureau						
* See the attached detailed Office action for a list	of the certified copies n	ot received.				
Attachment(s)	·					
Notice of References Cited (PTO-892)		w Summary (PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	lo(s)/Mail Date of Informal Patent Application					
B) Minformation Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date	6)  Other: _					
·						

Art Unit: 1616

### **Non-Final Office Action**

Claims 1-11, 17, 18, 20, 22, 24, 26 and 28 are pending. No claim is allowed at this time.

Amendments are entered.

Page 2

## Summary of this Office Action dated December 06, 2006

- 1. Information Disclosure Statement
- 2. Copending Applications
- 3. Specification
- 4. Double Patenting rejection
- 5. Closest Prior art
- 6. Communication

3

Art Unit: 1616

#### **Copending Applications**

Applicants must bring to the attention of the examiner, or other Office official involved with the examination of a particular application, information within their knowledge as to other copending United States applications, which are "material to patentability" of the application in question. MPEP 2001.06(b). See Dayco Products Inc. v. Total Containment Inc., 66 USPQ2d 1801 (CA FC 2003).

#### **Specification**

The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.

#### **Double Patenting Rejection**

1. A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

2. Claims 1-11, 17, 18, 20, 22, 24, 26 and 28 provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-11, 17, 18, 20, 22, 24, 26 and 28 of copending

Art Unit: 1616

Application No.10/821,479. This is a <u>provisional</u> double patenting rejection since the conflicting claims have not in fact been patented.

3. Instant claims are drawn to 2-hydroxypropylidine 19-nor vitamin D 3 compounds and their composition, which has been claimed in the co-pending application 10/821,479.

#### Closest prior art

Closest prior art is DeLuca et al. US Patent 6,806,262, WO 01/92221 and EP 1,524, 264. These references do not teach 2-(3'-hydroxypropylidine-1alpha, 25-dihydroxy-19-nor vitamin D3 compounds as presently claimed.

### **Contact Information**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sabiha Qazi whose telephone number is 571-272-0622. The examiner can normally be reached on any business day.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

Art Unit: 1616

Page 5

applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SABIHA QAZI, PH.D PRIMARY EXAMINER